Patents by Inventor Yoshihiro Omachi
Yoshihiro Omachi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220409655Abstract: The present invention relates to a platelet aggregating agent containing amorphous polyphosphate as an active ingredient, wherein the polyphosphate is a Ca salt of polyphosphate. The platelet aggregating agent acts on damaged gastrointestinal mucosa in inflammatory bowel disease and exerts a platelet aggregating action, thereby allowing remission/improvement of the inflammatory bowel disease.Type: ApplicationFiled: January 7, 2021Publication date: December 29, 2022Inventors: Mikihiro FUJIYA, Hiroaki KONISHI, Hiroki TANAKA, Shotaro ISOZAKI, Yoshihiro OMACHI, Naoki OGAWA
-
Patent number: 10668260Abstract: The present invention provides a microneedle patch which can solve the problem that microneedle production is difficult and requires high accuracy, the problem that time and mental burdens on a health professional and a patient are large, and the problem caused by compounding a plurality of drugs. The microneedle patch comprises a large number of drug-carrying microprojections 4 erected on one support sheet, each microprojection 4 having a drug layer 5 soluble in vivo at its top part and having an intermediate layer 6 under the drug layer 5, the intermediate layer 6 containing a polymeric substance for adhesion of the drug layer 5 to the support sheet, the drug layer 5 at the top part of the microprojection 4 containing a single drug, the microprojections 4 holding difference types of drugs being arranged together on the support sheet 2.Type: GrantFiled: March 11, 2014Date of Patent: June 2, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Omachi, Yasuhiro Hiraishi, Masami Kusaka, Shigehiro Asano, Masao Nagao
-
Publication number: 20160310412Abstract: In order to configure a microneedle to be more suitable for administering a vaccine antigen, the present invention is a formulation having a dissolving-type microspike which is used as a microneedle in which a vaccine antigen is stabilized, and which includes a vaccine antigen, an ionic polymer base material, and at least one species selected from the group consisting of a non-reducing sugar, a sugar alcohol, cyclodextrin, and a surfactant.Type: ApplicationFiled: December 15, 2014Publication date: October 27, 2016Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yutaka TANOUE, Yumiko ISHII, Yoshihiro OMACHI, Tomoyuki MANOSHIRO
-
Patent number: 9427434Abstract: The present invention provides a preparation containing pioglitazone or a salt thereof as an active ingredient, which shows high bioavailability of pioglitazone and less interindividual variation in blood drug concentration, as well as a preparation with suppressed color change during preservation. The preparation contains a core containing a pharmaceutically acceptable organic acid with water solubility at 20° C. of not less than 10 mg/mL and pKa1 (a negative common logarithm of the first acid dissociation constant Ka1) at 25° C. of not more than 5, and a coating layer containing pioglitazone or a salt thereof. The coating layer may further contain mannitol or trehalose.Type: GrantFiled: July 10, 2008Date of Patent: August 30, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Hiroto Bando, Yoshihiro Omachi, Kenichiro Kiyoshima
-
Patent number: 9241910Abstract: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient.Type: GrantFiled: March 10, 2009Date of Patent: January 26, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Takashi Kurasawa, Yasuko Watanabe, Yoshihiro Omachi
-
Publication number: 20160015952Abstract: The present invention provides a microneedle patch which can solve the problem that microneedle production is difficult and requires high accuracy, the problem that time and mental burdens on a health professional and a patient are large, and the problem caused by compounding a plurality of drugs. The microneedle patch comprises a large number of drug-carrying microprojections 4 erected on one support sheet, each microprojection 4 having a drug layer 5 soluble in vivo at its top part and having an intermediate layer 6 under the drug layer 5, the intermediate layer 6 containing a polymeric substance for adhesion of the drug layer 5 to the support sheet, the drug layer 5 at the top part of the microprojection 4 containing a single drug, the microprojections 4 holding difference types of drugs being arranged together on the support sheet 2.Type: ApplicationFiled: March 11, 2014Publication date: January 21, 2016Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro OMACHI, Yasuhiro HIRAISHI, Masami KUSAKA, Shigehiro ASANO, Masao NAGAO
-
Publication number: 20150037423Abstract: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Inventors: Takashi KURASAWA, Yasuko WATANABE, Yoshihiro OMACHI
-
Publication number: 20110091563Abstract: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient.Type: ApplicationFiled: March 10, 2009Publication date: April 21, 2011Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takashi Kurasawa, Yasuko Watanabe, Yoshihiro Omachi
-
Publication number: 20100166853Abstract: The present invention provides a preparation containing pioglitazone or a salt thereof as an active ingredient, which shows high bioavailability of pioglitazone and less interindividual variation in blood drug concentration, as well as a preparation with suppressed color change during preservation. The preparation contains a core containing a pharmaceutically acceptable organic acid with water solubility at 20° C. of not less than 10 mg/mL and pKa1 (a negative common logarithm of the first acid dissociation constant Ka1) at 25° C. of not more than 5, and a coating layer containing pioglitazone or a salt thereof. The coating layer may further contain mannitol or trehalose.Type: ApplicationFiled: July 10, 2008Publication date: July 1, 2010Inventors: Hiroto Bando, Yoshihiro Omachi, Kenichiro Kiyoshima